Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by C10H12N2on Dec 23, 2022 5:36pm
149 Views
Post# 35190546

RE:RE:Fact or Fiction?

RE:RE:Fact or Fiction?I'm not here to explain moral character or Christopher Moreau's judgment of character. I assume you're all adults reading what's written in black and white. There is ZERO dispute of the information being accurate unless you live in an alternative universe filled with alternative facts. A piece of advice here.. you invest in the people running the company more than the idea of the company itself. Think of it in terms of weak links. There's been an ungodly amount of mishaps at Algernon Pharmaceuticals since inception. The stock is down more than 90% since the current CEO took the helm. Yeah, I guess the buck stops nowhere for many penny stock investors. You'll have plenty of time to do some soul searching before you ever see a return on investment if ever. The DMT Phase 1 will not move the needle and you will not see any Phase II data readouts/results for at least 4 years c9ming out of Algernon's pipeline if they ever get funding. It looks now as though the next capital raise will come at another historic low fire sale price. I wouldn't doubt AlphaNorth gains a minimum of 25% ownership of Algernon Pharmaceuticals. Wall Street doesn't want anything to do with throwing money at Algernon's "ideas". Do you think it has anything to do with Algernon's plans or the man at the helm of the plan? How did that Wonderland event go where the CEO was the headliner? Anybody know how much that costs shareholders? Along with that previous insane blitz of gobbledygook news releases by that stock promoter NIA (I think that's their name). How much did that cost shareholders? What's known is the stock continues to drop. My best guess is it will eventually drop below 1 dollar Canadian and/or USD currency. Take your pick! Meanwhile, enjoy your 100 to 1 reverse split stock stuck in penny world - not NASDAQ - in perpetuity.
 
<< Previous
Bullboard Posts
Next >>